Lipella Pharmaceuticals Inc. (LIPO) Research

Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.

Market snapshot

Symbol
LIPO
Price
$0.08
Day change
+45.45%
Market cap
$369.7K
P/E ratio
-0.07x
52-week range
0.02-2.36
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$2.00

Peer companies

  • Artelo Biosciences, Inc. (ARTL)
  • Azitra, Inc. (AZTR)
  • Dermata Therapeutics, Inc. (DRMA)
  • GT Biopharma, Inc. (GTBP)
  • Indaptus Therapeutics, Inc. (INDP)
  • NKGen Biotech, Inc. Common Stock (NKGN)
  • Psyence Biomedical Ltd. (PBM)
  • Protagenic Therapeutics, Inc. (PTIX)

Recent insider activity

  • Kaufman Jonathan H — J-Other (536959 shares) on 2025-04-03
  • Kaufman Jonathan H — J-Other (4060 shares) on 2025-04-03
  • Kaufman Jonathan H — J-Other (10326 shares) on 2025-03-13
  • Kaufman Jonathan H — J-Other (4060 shares) on 2025-03-13
  • Kaufman Jonathan H — J-Other (84700 shares) on 2025-03-10

Open Lipella Pharmaceuticals Inc. (LIPO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.